Tuesday, November 24

The US approves the use of Regeneron’s treatment against Covid-19 that Donald Trump used


Sunday, 22 November 2020 – 09:51

It is a combination of two antibodies manufactured in the laboratory and reduces hospitalizations or visits to the emergency room of patients with Covid-19 with secondary diseases or “comorbidities”.

US President Donald Trump this s

US President Donald Trump this Saturday playing golf.
JIM LO SCALZO EFE

  • Live.

    last hour of the coronavirus

Faced with the uncontrolled advance of the Covid-19 epidemic, which has infected 12 million people in its territory, the US has authorized the use of a treatment from the firm Regeneron, previously used by the president Donald Trump when he was sick.

The United States is by far the country with the most deaths in the world from the coronavirus, with 255,800 deaths. The epidemic is out of control and the number of new daily cases is skyrocketing (almost 164,000 on Saturday alone) and already exceeds 12 million infections, according to Johns Hopkins University.

Faced with this situation, the United States Drug Agency (FDA) this Saturday granted urgent authorization to a cocktail of synthetic antibodies from the biotechnology company Regeneron. This treatment was administered to Trump, who had promoted it after recovering from Covid-19 in October.

According to the FDA, treatment with REGEN-COV2, a combination of two laboratory-made antibodies, has been shown to reduce hospitalizations or emergency room visits of Covid-19 patients with secondary diseases or “comorbidities”. “Licensing these monoclonal antibody therapies can help outpatients avoid being hospitalized and ease the burden on our healthcare system“said Stephen Hahn, commissioner of the US Food and Drug Administration (FDA).

“Promising therapy”

Regeneron’s president, Leonard Schleifer, added that this decision represents “an important step in the fight against Covid-19, as high-risk patients in the United States will have access to promising therapy at an early stage of their infection.” .

These antibodies mimic what the immune system does after contracting Covid-19 by blocking the tip of the virus allowing it to adhere and penetrate human cells.

This treatment is most effective during the initial phase of infection, when the antibodies still have a chance to control the invader, and not during the second phase, when the danger is no longer the virus, but the overreaction of the immune system that attacks the viruses. lungs and other organs.

Regeneron’s is the second synthetic antibody treatment to receive emergency approval from the FDA, after a similar therapy developed by Eli Lilly achieved that status on November 9.

The company received more than 450 million dollars from the US government for the development of treatments to fight against Covid-19 within the operation ‘Warp Speed’ (maximum speed), created by Trump to immunize the American population. The White House also announced in late October the purchase of 300,000 doses of Lilly’s treatment for $ 375 million, at $ 1,250 per dose.

The clearance granted to Regeneron is the latest in the hopeful news in the fight against coronavirus, after the Pfizer / BioNTech and Moderna vaccine projects announced efficiencies close to 95%.

According to the criteria of

The Trust Project

Know more



style="display:block" data-ad-client="ca-pub-3066188993566428" data-ad-slot="4073357244" data-ad-format="auto" data-full-width-responsive="true">
www.elmundo.es

Leave a Reply

Your email address will not be published. Required fields are marked *